Blood Test Spots Lung Cancer Recurrence Early

Researchers have developed a novel blood test capable of detecting lung cancer recurrence significantly earlier than traditional imaging methods. This liquid biopsy technology monitors circulating tumor DNA, providing real-time genetic insights into cancer relapse. It has demonstrated the ability to identify molecular evidence of recurrence in patients with stage IA lung adenocarcinoma, often more than 16 months before it would be visible on scans.

The study focused on patients with non-small-cell lung cancer (NSCLC) who had undergone surgery. The test achieved 75 percent sensitivity and 83 percent specificity in predicting recurrence. A positive blood test result indicates residual disease, while a negative result suggests sustained remission. This minimally invasive approach could help clinicians identify patients who might benefit from closer monitoring or additional treatment, while potentially sparing others from unnecessary interventions.

While the findings are highly encouraging, further prospective validation in larger patient populations is essential. Experts emphasize that additional trials are necessary before this blood test can become a standard of care for monitoring cancer recurrence. The goal is to refine testing schedules and integrate these results with imaging and treatment decisions to personalize patient care and improve long-term survival rates.